Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

Authors

Brian K Chen
Y Tony Yang, George Washington University
Charles L Bennett

Document Type

Journal Article

Publication Date

11-16-2018

Journal

Drugs

DOI

10.1007/s40265-018-1009-0

Comments

Epub ahead of print

APA Citation

Chen, B., Yang, Y., & Bennett, C. (2018). Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.. Drugs, (). http://dx.doi.org/10.1007/s40265-018-1009-0

Peer Reviewed

1